GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Qingdao Haier Biomedical Co Ltd (SHSE:688139) » Definitions » EBIT

Qingdao Haier Biomedical Co (SHSE:688139) EBIT : ¥441 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Qingdao Haier Biomedical Co EBIT?

Qingdao Haier Biomedical Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥156 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥441 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Qingdao Haier Biomedical Co's annualized ROC % for the quarter that ended in Mar. 2024 was 17.32%. Qingdao Haier Biomedical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 71.73%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Qingdao Haier Biomedical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 4.10%.


Qingdao Haier Biomedical Co EBIT Historical Data

The historical data trend for Qingdao Haier Biomedical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qingdao Haier Biomedical Co EBIT Chart

Qingdao Haier Biomedical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 211.42 424.32 963.76 678.02 438.00

Qingdao Haier Biomedical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 152.88 156.26 85.33 43.54 155.54

Competitive Comparison of Qingdao Haier Biomedical Co's EBIT

For the Medical Devices subindustry, Qingdao Haier Biomedical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qingdao Haier Biomedical Co's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Qingdao Haier Biomedical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Qingdao Haier Biomedical Co's EV-to-EBIT falls into.



Qingdao Haier Biomedical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥441 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qingdao Haier Biomedical Co  (SHSE:688139) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Qingdao Haier Biomedical Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=581.876 * ( 1 - 8.31% )/( (3130.984 + 3031.004)/ 2 )
=533.5221044/3080.994
=17.32 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5525.683 - 800.334 - ( 1920.42 - max(0, 941.663 - 2536.028+1920.42))
=3130.984

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5686.836 - 894.761 - ( 2001.189 - max(0, 987.89 - 2748.961+2001.189))
=3031.004

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Qingdao Haier Biomedical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=622.176/( ( (862.218 + max(-333.393, 0)) + (872.658 + max(-235.873, 0)) )/ 2 )
=622.176/( ( 862.218 + 872.658 )/ 2 )
=622.176/867.438
=71.73 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(187.678 + 248.019 + 151.77) - (800.334 + 0 + 120.526)
=-333.393

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(334.708 + 250.845 + 140.928) - (894.761 + 0 + 67.593)
=-235.873

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Qingdao Haier Biomedical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=440.665/10741.640
=4.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qingdao Haier Biomedical Co EBIT Related Terms

Thank you for viewing the detailed overview of Qingdao Haier Biomedical Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Qingdao Haier Biomedical Co (SHSE:688139) Business Description

Traded in Other Exchanges
N/A
Address
No.1 Haier Road, Branding Building, Qingdao, CHN, 266101
Qingdao Haier Biomedical Co Ltd is engaged in designing, manufacturing, marketing and sales of low temperature storage equipment for biomedical samples. The company provides provides complete storage solutions for biological sample banks, blood safety, vaccine safety, medical supplies and reagent safety.
Executives
Zhang Jiang Tao Core technical personnel
Liu Ji Yuan Core technical personnel
Teng Pei Kun Core technical personnel
Wang Guang Sheng senior management
Gong Yi Director
Huang Yan Li senior management
Chen Hai Tao Senior management, core technical personnel
Liu Zhan Jie Directors, senior managers, core technical personn
Mo Rui Juan senior management
Wang Wen Fu Director

Qingdao Haier Biomedical Co (SHSE:688139) Headlines

No Headlines